Deciphering N⁶-Methyladenosine-Related Genes Signature to Predict Survival in Lung Adenocarcinoma

Figure 5

The relationship between the signature genes and the different clinicopathological parameters. (a) and (b) Patients with higher pathological stages tend to have higher risk scores. (c) and (d) Patients with higher pathological stages tend to have higher HNRNPC expressions. (e) and (f) Older patients and patients with higher pathological stages tend to have lower METTL3 expressions. (g) and (h) Patients with higher N stages and pathological stages tend to have lower YTHDC2 expressions. (i) Patients with higher pathological stages tend to have lower YTHDF1 expressions.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)